Halozyme Therapeutics Inc
HALO69.211USD
+1.161+1.71%
Market hours （ET）Quotes delayed by 15 min
8.13BMarket Cap
14.60P/E TTM
More Details of Halozyme Therapeutics Inc Company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Halozyme Therapeutics Inc Info
Ticker SymbolHALO
Company nameHalozyme Therapeutics Inc
IPO dateJan 30, 2003
CEODr. Helen I. Torley
Number of employees350
Security typeOrdinary Share
Fiscal year-endJan 30
Address12390 El Camino Real
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92130
Phone18587948889
Websitehttps://www.halozyme.com/
Ticker SymbolHALO
IPO dateJan 30, 2003
CEODr. Helen I. Torley
Company Executives of Halozyme Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
733.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
22.08K
-30.79%
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.67K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Ms. Barbara Duncan
Ms. Barbara Duncan
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
733.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
22.08K
-30.79%
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.67K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
205.64M
63.13%
Sales of proprietary products
46.45M
14.26%
Event-based development and regulatory milestones and other fees
24.50M
7.52%
Sales of bulk rHuPH20
23.27M
7.14%
Sales of device partnered products
11.79M
3.62%
Other
14.07M
4.32%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
205.64M
63.13%
Sales of proprietary products
46.45M
14.26%
Event-based development and regulatory milestones and other fees
24.50M
7.52%
Sales of bulk rHuPH20
23.27M
7.14%
Sales of device partnered products
11.79M
3.62%
Other
14.07M
4.32%
Shareholding Stats
Updated: Tue, Nov 4
Updated: Tue, Nov 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.45%
BlackRock Institutional Trust Company, N.A.
10.01%
State Street Investment Management (US)
5.07%
Snyder Capital Management, L.P.
2.90%
Arrowstreet Capital, Limited Partnership
2.17%
Other
69.39%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.45%
BlackRock Institutional Trust Company, N.A.
10.01%
State Street Investment Management (US)
5.07%
Snyder Capital Management, L.P.
2.90%
Arrowstreet Capital, Limited Partnership
2.17%
Other
69.39%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.30%
Investment Advisor/Hedge Fund
32.22%
Hedge Fund
5.10%
Research Firm
4.87%
Pension Fund
2.95%
Bank and Trust
1.59%
Individual Investor
1.16%
Sovereign Wealth Fund
0.89%
Venture Capital
0.21%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1088
121.11M
103.55%
-10.64M
2025Q2
1037
125.48M
107.21%
-10.05M
2025Q1
1043
127.91M
103.79%
-10.64M
2024Q4
999
127.73M
103.64%
-14.45M
2024Q3
953
129.39M
102.16%
-10.33M
2024Q2
905
126.24M
99.18%
-14.91M
2024Q1
870
127.71M
100.45%
-13.70M
2023Q4
850
128.82M
97.51%
-11.71M
2023Q3
836
127.73M
96.80%
-13.97M
2023Q2
838
128.24M
97.33%
-12.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
12.22M
10.45%
-584.32K
-4.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.71M
10.01%
-3.28M
-21.88%
Jun 30, 2025
State Street Investment Management (US)
5.94M
5.07%
-117.96K
-1.95%
Jun 30, 2025
Snyder Capital Management, L.P.
3.40M
2.9%
-276.61K
-7.53%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
2.54M
2.17%
+1.43M
+127.81%
Jun 30, 2025
AllianceBernstein L.P.
2.46M
2.1%
-759.84K
-23.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.43M
2.08%
-736.73K
-23.25%
Jun 30, 2025
Macquarie Investment Management
2.08M
1.78%
-594.59K
-22.23%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.01M
1.72%
-14.43K
-0.71%
Jun 30, 2025
Invesco Capital Management LLC
1.77M
1.51%
-647.08K
-26.77%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
LSV Disciplined Value ETF
19.22%
First Trust NYSE Arca Biotechnology Index Fund
4.16%
Future Fund Long/Short ETF
3.98%
Janus Henderson Small/Mid Cap Growth Alpha ETF
2.74%
Congress SMid Growth ETF
2.7%
Invesco Biotechnology & Genome ETF
2.69%
Invesco S&P MidCap 400 GARP ETF
2.49%
Alpha Architect US Quantitative Value ETF
2.36%
Virtus LifeSci Biotech Products ETF
2.24%
SPDR S&P Biotech ETF
2%
View more
LSV Disciplined Value ETF
Proportion19.22%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.16%
Future Fund Long/Short ETF
Proportion3.98%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion2.74%
Congress SMid Growth ETF
Proportion2.7%
Invesco Biotechnology & Genome ETF
Proportion2.69%
Invesco S&P MidCap 400 GARP ETF
Proportion2.49%
Alpha Architect US Quantitative Value ETF
Proportion2.36%
Virtus LifeSci Biotech Products ETF
Proportion2.24%
SPDR S&P Biotech ETF
Proportion2%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
